Back to discover
Disease

Peanut Hypersensitivity

Active therapeutic pipelineEmerging research
MeSHPeanut Hypersensitivity
1
Publications
8
Clinical trials
2018
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

AR101 Oral Immunotherapy for Peanut Allergy.

Research2018-11-18The New England journal of medicine

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 2 clinical trials with recent milestones (1 completed or reporting results).
Clinical Milestones2View
Results posted 1
Recently completed 1
Activity timeline2

Clinical trials

5 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
8
All trials
2
Active
0
Late-stage
6
Completed
Recently completed

Peanut Sublingual Immunotherapy Induction of Clinical Tolerance of Newly Diagnosed Peanut Allergic 12 to 48 Month Old Children

Phase 2 · Completed · University of North Carolina, Chapel Hill

Oral Immunotherapy for Induction of Tolerance and Desensitization in Peanut-Allergic Children (ITN050AD)

Phase 2 · Completed · National Institute of Allergy and Infectious Diseases (NIAID)

Peanut Sublingual Immunotherapy and Induction of Clinical Tolerance in Peanut Allergic Children (SLIT Tolerance TLC) {Sublingual Immunotherapy for Peanut Allergy}

Phase 1/2 · Completed · University of North Carolina, Chapel Hill

Oral Immunotherapy for Peanut Allergy- Peanut Oral Immunotherapy (PnOIT3)

Phase 2 · Completed · University of North Carolina, Chapel Hill

Epicutaneous Immunotherapy (EPIT) for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled, Phase II Study in Children and Adults (DAIT COFAR6)

Phase 2 · Completed · National Institute of Allergy and Infectious Diseases (NIAID)

A Phase IIb, Open-Label Study of Xolair (Omalizumab) in Peanut-Allergic Subjects Randomized to Study Drug in Study Q2788g (TOPS)

Phase 2 · Completed · Genentech, Inc.

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

AR101 Oral Immunotherapy for Peanut Allergy.

The New England journal of medicine · 2018 · 524 cites
Recent publications

AR101 Oral Immunotherapy for Peanut Allergy.

The New England journal of medicine · 2018 · 524 cites
Leading journals1
  • The New England journal of medicine1
Leading researchers8
  • Adelman DC1
  • Anagnostou A1
  • Assa’ad AH1
  • Ben-Shoshan M1
  • Beyer K1
  • Bindslev-Jensen C1
  • Bird JA1
  • Blumchen K1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Allergic reaction to peanuts that is triggered by the immune system.

Identifiers
MeSHPeanut Hypersensitivity
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.